(IN BRIEF) Roche and Nurix Therapeutics have entered into an exclusive global licensing and collaboration agreement to co-develop and co-commercialise bexobrutideg, also known as NX-5948, an investigational oral BTK degrader with potential applications across malignant haematology, immunology and neurology. The … Read the full press release
Posted in Business, European Union, Financial, Government, Healthcare, Industrial, Investment, Law, Management, Marketing, Pharma & Biotech, Science, Switzerland, Technology
Tagged Arthur T Sands, B-cell malignancies, bexobrutideg, brain-penetrant therapy, Bruton’s tyrosine kinase, BTK, BTK degrader, BTK inhibitors, chronic lymphocytic leukaemia, chronic spontaneous urticaria, CLL, co-commercialisation, co-development, CSU, Hart-Scott-Rodino Antitrust Improvements Act, immunology, Immunology and Neurology Pipeline with Global Bexobrutideg Collaboration, kinase activity, Levi Garraway, licensing agreement, malignant haematology, MS, multiple sclerosis, Neurology, NHL, Non-Hodgkin lymphoma, Nurix Therapeutics, NX-5948, oncology pipeline, oral therapy, Phase 3 clinical trial, relapsed or refractory B-cell malignancies, Roche, Roche and Nurix Announce Up to USD 2.3 Billion Collaboration to Develop and Commercialise Bexobrutideg, Roche and Nurix Therapeutics Partner on Potential Best-in-Class Targeted Protein Degrader for B-Cell Malignancies, Roche oncology, Roche Strengthens Oncology, scaffolding function, Switzerland, targeted protein degradation, targeted protein degrader, treatment resistance, United States, USD 2.3 billion deal value, USD 700 million upfront payment
(IN BRIEF) Researchers at The Institute of Cancer Research, London have created a next-generation PROTAC degrader that successfully eliminates the cancer-related protein Aurora A while overcoming the hook effect that has limited earlier degraders. The new molecule, CCT400028, demonstrates improved … Read the full press release
Posted in Business, Education, Financial, Healthcare, Industrial, Investment, Management, Pharma & Biotech, Science, Technology, United Kingdom
Tagged alisertib, Aurora A kinase, Cancer Research UK, cancer therapeutics, CCT400028, chemical probes, Children’s Brain Tumour Centre of Excellence CBTCE, Gary Newton, glioma, hook effect, Institute of Cancer Research Develops Advanced Aurora A PROTAC Degrader That Overcomes Hook Effect and Improves Stability, Institute of Cancer Research London, Journal of Medicinal Chemistry, leukaemia, Lindsay Evans, Neuroblastoma, New Aurora A Degrader from Institute of Cancer Research Demonstrates Improved Selectivity and Reliability in Cancer Studies, paediatric cancers, Paul Workman, PROTAC, protein degradation technology, targeted protein degradation, University of Kiel
(IN BRIEF) The Institute of Cancer Research and NEOsphere Biotechnologies have announced a new collaboration to accelerate the discovery of molecular glue degrader drugs, an innovative approach in targeted cancer therapy. The partnership will integrate ICR’s proprietary molecular glue library … Read the full press release
Posted in Business, Education, Healthcare, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged Academic–industry partnership to accelerate rational design of molecular glue degrader drugs for cancer treatment, artificial intelligence, Cancer Drug Discovery, cancer research innovation, Centre for Protein Degradation, computational drug design, E3 ligases, Henrik Daub, high-throughput proteomics, ICR, ICR and NEOsphere Biotechnologies join forces to pioneer systematic discovery of molecular glue degrader therapies, Institute of Cancer Research, Institute of Cancer Research and NEOsphere Biotechnologies partner to advance molecular glue degrader drug discovery, Jonathan Beech, Machine Learning, MGDs, molecular glue degraders, molecular glue library, Monte Rosa Therapeutics, Nature Communications, NEOsphere Biotechnologies, Novartis, proteomics, St Jude Children’s Research Hospital, targeted protein degradation, Zoran Rankovic
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?